Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting September 27, 2006 Barbara L. Mulach, Ph.D. National Institute.

Slides:

Advertisements

Similar presentations

Trends in Adult Vaccination Coverage Internal for NAIIS Provider Workgroup March Meeting Preliminary Data National Health Interview Survey

Advertisements

AMMI Canada /CPHA Co-developed Accredited Learning Activity December 3, 2014 Dat Tran, MD, MSc Staff Physician, Division of Infectious Diseases The Hospital.

1 Avian Influenza Bird Flu H5N1. 2 Avian Influenza… Is a respiratory illness in birds Wild birds and ducks are the natural reservoir for infection, though.

Vaccines and Related Biological Products

Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.

Pre-2003 Pandemic Influenza Vaccine Goal & Strategy

VIRAL AND ZOONOTIC DISEASE RESEARCH PROGRM VZDRP Study. Monitor. Detect Empowering nations and agencies through collaboration, with the means to better.

INFLUENZA. VIROLOGY OF INFLUENZA Subtypes: A - Causes outbreak B - Causes outbreaks C - Does not cause outbreaks.

Medical Diagnostics NIAID Funding Opportunities Maria Y. Giovanni, Ph.D. Assistant Director for Microbial Genomics and Advanced Technologies National Institute.

Clinical Outcomes of Influenza Infection Asymptomatic Asymptomatic Symptomatic Symptomatic  Respiratory syndrome - mild to severe  Involvement of major.

1. 2 The Public Health Agency of Canada Pandemic Influenza Preparedness: An Overview Dr. Paul Gully Deputy Chief Public Health Officer Ottawa, 19 January.

National Vaccine Advisory Committee June 7, 2005 Pandemic Influenza Vaccine Research and Development Linda C. Lambert Chief, Respiratory Diseases Branch.

Avian Influenza - Pandemic Threat ? Reinhard Bornemann.

National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.

0 HHS Influenza Vaccine Projects for NVAC Meeting November 29-30, 2005 By: Dr. Robin Robinson Sr. Project Officer ORDC/OPHEP/DHHS.

Adult Immunization 2010 Influenza Segment This material is in the public domain This information is valid as of May 25, 2010.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Smallpox and Influenza "In early 1962 long queues attended any clinic in Birmingham offering vaccination, because three patients with smallpox were in.

Pandemic Influenza Preparedness Kentucky Department for Public Health Department for Public Health.

Epidemic Vs Pandemic 8.L.1.2.

HealthSanté CanadaCanada Influenza Prevention and Control in Canada Arlene King, MD, MHSc, FRCPC Director, Immunization and Respiratory Infections Division,

EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global epidemics Influenza viruses.

EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global pandemics Influenza viruses.

Vaccines and Related Biological Products Advisory Committee Presentation on Sanofi Pasteur’s H5N1 Vaccine Andrea N. James, M.D. Senior Medical Officer.

0 H1N1 Vaccines VRBPAC Meeting Robin Robinson, Ph.D. HHS/ASPR/BARDA Director July 23, 2009.

Influenza Surveillance at IRID Immunization and Respiratory Infections Division Centre for Infectious Disease Prevention & Control Public Health Agency.

Influenza Vaccine Development

Raymond A. Strikas, MD Associate Director for Adult Immunization Immunization Services Division National Immunization Program Coordinating Center for Infectious.

NIAID Commitment to Influenza Research and Preparedness F. Gray Handley Associate Director for International Research Affairs National Institute of Allergy.

Surveillance Activities during Pandemic Phases Anne-Luise Winter APHEO-COMOH Workshop Toronto February 1, 2007.

Review and Discussion Time line courtesy of:

U.S. Influenza Surveillance Keiji Fukuda Influenza Branch National Center for Infectious Diseases Centers for Disease Control and Prevention.

Dr. Zhen XU Branch of Respiratory Disease Prevention and Control Division for Disease Control and Emergency Response Chinese Center for Disease Control.

Avian Influenza "bird flu" Contagious disease of animals caused by viruses that normally infect only birds and pigs H5N1 can infect people (very rarely)

World Health Organization, Regional Office for The Western Pacific Regional Activities Report and Preparation for the Upcoming Influenza Seasons THE 3rd.

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

Food and Drug Administration

Influenza Today Joseph Mester, Ph.D. September 24, 2009.

Avian Influenza H5N1 Prepared by: Samia ALhabardi.

The Vermont Department of Health Overview of Pandemic Influenza Regional Pandemic Planning Summits 2006 Guidance Support Prevention Protection.

FDA/CBER Vaccines and Related biological Products Advisory Committee Meeting Discussion of Clinical Trials to Support use of Vaccines against the 2009.

Influenza biology and epidemiology. The course of illness  Symptoms  Fever, headache, body aches, fatigue  Cough, sore throat, runny nose  Duration:

VRBPAC Topic #2: Clinical Development of Influenza Vaccines for Pre-pandemic Use Joseph G. Toerner, MD, MPH VCTB/DVRPA/OVRR/CBER/FDA February 27, 2007.

INFLUENZA UPDATE DEBBYE ROSEN ADULT IMMUNIZATION COORDINATOR CONNECTICUT DEPARTMENT OF PUBLIC HEALTH

Pandemic Vaccines Current and Future Issues 30 January 2007 Beijing Keiji Fukuda Global Influenza Programme.

(CAREC) PAHO/WHO Serving 21 Member Countries in the English and Dutch Speaking Caribbean 2009 Pandemic Influenza in CAREC Member Countries: Summary and.

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Two: Controlling Animal Influenza.

What Is H1N1 (Swine Flu) Pandemic Influenza? Colorized image of H1N1 from a transmission electron micrograph. Source: CDC.

Update on the Development of a Group A Streptococcal Vaccine Fran A. Rubin, Ph.D. Program Officer for Group A Streptococci Respiratory Diseases Branch.

Update from the 2010 National Influenza Vaccine Summit meeting L.J Tan Co-chair, National Influenza Vaccine Summit Director, Medicine and Public Health,

1 H5N1 Influenza Virus Vaccine, A/Vietnam/1203/2004 (Clade 1) VRBPAC Presentation Kenneth P. Guito, MBA Strategic Project Office.

1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.

Novartis Vaccines - Influenza A H1N1v vaccine development Theodore F Tsai MD MPH July 23, 2009 DHHS supported influenza cell culture vaccine production.

Lisa Grohskopf, MD, MPH U.S. Influenza Surveillance Season National Center for Immunization & Respiratory Diseases Influenza Division U.S. Food.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

1 Vaccines and Related Biological Products Advisory Committee Meeting FluBlok ® : Influenza Vaccine, Recombinant Hemagglutinin Applicant: Protein Sciences.

Carol Friedman, D.O. Associate Director for Adult Immunization Immunization Services Division National Center for Immunization and Respiratory Diseases.

1 Considerations in the Pre- and Early Pandemic Use of Influenza Vaccine Jesse L. Goodman, MD, MPH Center for Biologics Evaluation and Research, VRBPAC,

CVD Testing the H1N1 Pandemic Flu Vaccines Mini-Med School Karen Kotloff, MD University of Maryland School of Medicine Center for Vaccine Development September.

Pandemic Influenza Vaccine Manufacture Preparedness Lin Su Sinovac Biotech Co., Ltd.

ACIP Recommendations Update for the U.S. Influenza Season

Texas Pediatric Society Texas Department of State Health Services October 6, 2009 Novel H1N1 in Texas Update for Providers Susan Penfield, MD David Scott.

Welcome! Thank you for joining the American College of Physicians’ Quality Connect Adult Immunization Learning Series Webinar! We will start in a few.

Influenza Vaccines: From Surveillance Through Production to Protection

Human- Environment Interaction

The Role of NICs in Influenza Surveillance

Modelling during an emergency: the 2009 H1N1 influenza pandemic

Influenza Experience: Highlights and Comments

Influenza algorithm for determining recommended 2009–2010 influenza immunization. a Contraindications: please refer to page 7 of the policy statement for.

Presentation transcript:

Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting September 27, 2006 Barbara L. Mulach, Ph.D. National Institute of Allergy and Infectious Diseases NIH/DHHS

NIAID Centers of Excellence for Influenza Research and Surveillance Goal Goal: To carry out an international and/or domestic animal surveillance program with emphasis on the rapid characterization of influenza viruses with pandemic potential; to carry out a research program to determine the factors that influence influenza viruses, and characterize the immune response to influenza infection and/or vaccination. BAA was announced October 18, 2005 BAA was announced October 18, 2005 Applications were due March 6, 2006 Applications were due March 6, 2006 Review is ongoing Review is ongoing Awards anticipated in December 2006 Awards anticipated in December 2006 Goal Goal: To carry out an international and/or domestic animal surveillance program with emphasis on the rapid characterization of influenza viruses with pandemic potential; to carry out a research program to determine the factors that influence influenza viruses, and characterize the immune response to influenza infection and/or vaccination. BAA was announced October 18, 2005 BAA was announced October 18, 2005 Applications were due March 6, 2006 Applications were due March 6, 2006 Review is ongoing Review is ongoing Awards anticipated in December 2006 Awards anticipated in December 2006

NIAID Influenza Diagnostics-Examples Emerging Diagnostic Technologies Advanced/Later Stage Product Development Applied/Early Stage Product Dev Multiplex Immunoassay Platform for Respiratory Viruses Multiplex PCR Detection Platform for Respiratory Viruses DNA/RNA Multiplex Platform/Chip for Influenza Detection and Subtyping Proteomics/Protein Diagnostic Arrays Nanotechnology Multiplex PCR-Mass Spectrometry Platform for Respiratory Viruses

H5N1 Vaccine Trials: Strategies to Enhance Immunogenicity Route: ID vs. IM administration Route: ID vs. IM administration Give a 3 rd dose of vaccine at 6 months Give a 3 rd dose of vaccine at 6 months Adult study completed Adult study completed Evaluate adjuvants Evaluate adjuvants H5N1 (sanofi) with and without AlOH H5N1 (sanofi) with and without AlOH H5N1 (Novartis) with and without AlOH or MF59 H5N1 (Novartis) with and without AlOH or MF59 H5N1 (Baxter-cell culture) with and without AlOH H5N1 (Baxter-cell culture) with and without AlOH Route: ID vs. IM administration Route: ID vs. IM administration Give a 3 rd dose of vaccine at 6 months Give a 3 rd dose of vaccine at 6 months Adult study completed Adult study completed Evaluate adjuvants Evaluate adjuvants H5N1 (sanofi) with and without AlOH H5N1 (sanofi) with and without AlOH H5N1 (Novartis) with and without AlOH or MF59 H5N1 (Novartis) with and without AlOH or MF59 H5N1 (Baxter-cell culture) with and without AlOH H5N1 (Baxter-cell culture) with and without AlOH